Roche: FY EPS up 19%

(CercleFinance.com) - Roche has published EPS of its core businesses that is up 19% (+8% excluding the impact of the US tax reform) at 18.
14 Swiss francs, and the board will propose that its dividend for 2018 be increased to 8.70 Swiss francs.

At over 56.8 billion Swiss francs, revenues increased by 7%, with similar growth at the pharma division, mainly boosted by Perjeca, Tecentriq, Alecensa and Hemlibra and - for its diagnostics division - thanks to the demand for immunodiagnostic solutions.

For 2019 and at constant exchange rates, according to Roche, “Sales are expected to grow in the low- to mid-single digit range.” Core earnings per share are targeted to grow broadly in line with sales.


Copyright (c) 2019 CercleFinance.com. All rights reserved.